At Dash Bio, we're revolutionizing bioanalysis to expedite drug development. By leveraging robotics and modern software, we deliver higher-quality assays with turnaround times up to 10x faster than the industry average, scaling seamlessly from preclinical through late-stage clinical studies.

While drug discovery has been revolutionized with AI and breakthrough modalities, the development phase remains bogged down by manual, labor-intensive processes. We're changing that narrative. Our tech-first products automate critical steps, reducing costs and time to market while improving quality of results.

Meet Our Leadership Team:

Dave Johnson, CEO: Former Chief Data and AI Officer at Moderna.

Ander Tallett, COO: Led Enterprise Systems at Moderna and Resilience.

Ely Porter, CSO: Co-founder and CTO of Rootpath.

Together, we're crafting a future where bioanalysis is intuitive, data flows effortlessly, and drugs reach the market faster than ever before.

Join us on this journey. Learn more at dash.bio